High-throughput screening for novel prostate cancer drug targets identifies PLA2G7 as a putative target for ERG oncogene positive cancers

P. Vainio, L. Lehtinen, Mika Hilvo, T. Mirtti, John Mpindi, Pekka Kohonen, Vidal Fey, K. Ketola, K. Alanen, Merja Perälä, Matej Oresic, Olli Kallioniemi, Kristiina Iljin

Research output: Chapter in Book/Report/Conference proceedingConference abstract in proceedingsScientific

Original languageEnglish
Title of host publicationMetabolomics 2010 abstract book
Subtitle of host publicationBreakthroughs in plant, microbial and human biology, clinical and nutritional research, and biomarker discovery
Pages135
Publication statusPublished - 2010
MoE publication typeNot Eligible
EventMetabolomics 2010: Breakthroughs in plant, microbial and human biology, clinical and nutritional research, and biomarker discovery - Amsterdam, Netherlands
Duration: 27 Jun 20101 Jul 2010

Conference

ConferenceMetabolomics 2010
CountryNetherlands
CityAmsterdam
Period27/06/101/07/10

Cite this

Vainio, P., Lehtinen, L., Hilvo, M., Mirtti, T., Mpindi, J., Kohonen, P., ... Iljin, K. (2010). High-throughput screening for novel prostate cancer drug targets identifies PLA2G7 as a putative target for ERG oncogene positive cancers. In Metabolomics 2010 abstract book: Breakthroughs in plant, microbial and human biology, clinical and nutritional research, and biomarker discovery (pp. 135)
Vainio, P. ; Lehtinen, L. ; Hilvo, Mika ; Mirtti, T. ; Mpindi, John ; Kohonen, Pekka ; Fey, Vidal ; Ketola, K. ; Alanen, K. ; Perälä, Merja ; Oresic, Matej ; Kallioniemi, Olli ; Iljin, Kristiina. / High-throughput screening for novel prostate cancer drug targets identifies PLA2G7 as a putative target for ERG oncogene positive cancers. Metabolomics 2010 abstract book: Breakthroughs in plant, microbial and human biology, clinical and nutritional research, and biomarker discovery. 2010. pp. 135
@inbook{92587b764c0442c0b36a51cfcf360e0e,
title = "High-throughput screening for novel prostate cancer drug targets identifies PLA2G7 as a putative target for ERG oncogene positive cancers",
author = "P. Vainio and L. Lehtinen and Mika Hilvo and T. Mirtti and John Mpindi and Pekka Kohonen and Vidal Fey and K. Ketola and K. Alanen and Merja Per{\"a}l{\"a} and Matej Oresic and Olli Kallioniemi and Kristiina Iljin",
year = "2010",
language = "English",
pages = "135",
booktitle = "Metabolomics 2010 abstract book",

}

Vainio, P, Lehtinen, L, Hilvo, M, Mirtti, T, Mpindi, J, Kohonen, P, Fey, V, Ketola, K, Alanen, K, Perälä, M, Oresic, M, Kallioniemi, O & Iljin, K 2010, High-throughput screening for novel prostate cancer drug targets identifies PLA2G7 as a putative target for ERG oncogene positive cancers. in Metabolomics 2010 abstract book: Breakthroughs in plant, microbial and human biology, clinical and nutritional research, and biomarker discovery. pp. 135, Metabolomics 2010, Amsterdam, Netherlands, 27/06/10.

High-throughput screening for novel prostate cancer drug targets identifies PLA2G7 as a putative target for ERG oncogene positive cancers. / Vainio, P.; Lehtinen, L.; Hilvo, Mika; Mirtti, T.; Mpindi, John; Kohonen, Pekka; Fey, Vidal; Ketola, K.; Alanen, K.; Perälä, Merja; Oresic, Matej; Kallioniemi, Olli; Iljin, Kristiina.

Metabolomics 2010 abstract book: Breakthroughs in plant, microbial and human biology, clinical and nutritional research, and biomarker discovery. 2010. p. 135.

Research output: Chapter in Book/Report/Conference proceedingConference abstract in proceedingsScientific

TY - CHAP

T1 - High-throughput screening for novel prostate cancer drug targets identifies PLA2G7 as a putative target for ERG oncogene positive cancers

AU - Vainio, P.

AU - Lehtinen, L.

AU - Hilvo, Mika

AU - Mirtti, T.

AU - Mpindi, John

AU - Kohonen, Pekka

AU - Fey, Vidal

AU - Ketola, K.

AU - Alanen, K.

AU - Perälä, Merja

AU - Oresic, Matej

AU - Kallioniemi, Olli

AU - Iljin, Kristiina

PY - 2010

Y1 - 2010

M3 - Conference abstract in proceedings

SP - 135

BT - Metabolomics 2010 abstract book

ER -

Vainio P, Lehtinen L, Hilvo M, Mirtti T, Mpindi J, Kohonen P et al. High-throughput screening for novel prostate cancer drug targets identifies PLA2G7 as a putative target for ERG oncogene positive cancers. In Metabolomics 2010 abstract book: Breakthroughs in plant, microbial and human biology, clinical and nutritional research, and biomarker discovery. 2010. p. 135